Receive a FREE Mesothelioma Treatment
Information Packet

Mesothelioma

Phase II Study Of Antineoplastons A10 And AS2-1 In Patients With Mesothelioma

 

Phase II Study Of Antineoplastons A10 And AS2-1 In Patients With Mesothelioma

Provide the treatment for incurable mesothelioma.
Evaluate the adverse effects and tolerance of Antineoplaston A10 and AS2-1 in these patients.

Inclusion Criteria:

Patients who have histologically confirmed, mesothelioma, stage IV and are unlikely to have a curative respond to existing standard regimen including surgery, radiation therapy and chemotherapy.
There will be no exclusion based on tumor size or systemic metastases.
Radiological evidence of tumor by gadolinium-enhanced MRI or contrast-enhanced CT scan, chest x-ray, or radionuclide scan, if necessary, performed within 14 days before initiating the treatment.
Patients who have previously received radiation therapy, chemotherapy, immunotherapy or cytodifferentiating agent are eligible.
Patients who did not receive standard therapy are eligible.

Location/Contact Information:
Salim Qazizadeh M.D.
S. R. Burzynski Clinic
9432 Old Katy, Suite 200
Houston, TX 77055
Telephone: 713-335-5697
Fax: 713-335-5699
Email: info@burzynskiclinic.com